{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:57:47Z","timestamp":1790135867934,"version":"4.0.1"},"reference-count":37,"publisher":"The Korean Association for the Study of the Liver","issue":"2","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272836"],"award-info":[{"award-number":["82272836"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403907"],"award-info":[{"award-number":["82403907"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","award":["22XD1400300"],"award-info":[{"award-number":["22XD1400300"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M750542"],"award-info":[{"award-number":["2024M750542"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["e-cmh.org"],"crossmark-restriction":true},"short-container-title":["Clin Mol Hepatol"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:p>Background\/Aims: Regorafenib is recommended by guidelines and trials as a sequential second-line therapy following progression on first-line sorafenib or lenvatinib in hepatocellular carcinoma (HCC). However, efficacy is limited, highlighting the urgent need to screen suitable patients and develop sensitization strategies.Methods: Acquired sorafenib- or lenvatinib-resistant (SR or LR) HCC cell lines and organoids were established. Genome-wide CRISPR library screen was performed in SR or LR cell strains to identify synthetic lethal targets of regorafenib. RNA-seq and FITC-regorafenib efflux assay were used to elucidate ERBB3-driven downstream signaling. Preclinical mouse models of cell line- and patient-derived xenografts and clinical cohorts of HCC patients were employed to validate the efficacy of ERBB3-guided patient stratification.Results: Screening with CRISPR library, we showed that inhibition of ERBB3 was synthetic lethal with regorafenib in SR or LR cell strains and organoids. Mechanistically, SR or LR triggered feedback activation of ERBB3 signaling and mediated regorafenib efflux via ERBB3-HIF1A-ABCB1 cascade pathway, limiting sensitivity to regorafenib. Moreover, ERBB3-low tumors following SR or LR exhibited significant sensitivity to regorafenib, suggesting its potential as a predictive biomarker to screen optimal candidates for sequential therapy. Seribantumab, an ERBB3-targeting monoclonal antibody, inhibited ERBB3-HIF1A-ABCB1 cascade, and its combination with regorafenib exerted marked synergistic anti-tumor effects on ERBB3-high tumors resistant to sorafenib or lenvatinib both in vitro and in vivo.Conclusions: This study revealed that ERBB3 was a key resistance factor driving limited efficacy to sequential regorafenib, but also an effective therapeutic target whose inhibition enhanced regorafenib sensitivity after SR or LR.<\/jats:p>","DOI":"10.3350\/cmh.2025.0972","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:34:13Z","timestamp":1768887253000},"page":"787-807","update-policy":"https:\/\/doi.org\/10.3350\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["ERBB3 blockade sensitizes hepatocellular carcinoma to regorafenib after first-line tyrosine kinase inhibitor resistance by inhibiting HIF1A-ABCB1 signaling"],"prefix":"10.3350","volume":"32","author":[{"given":"Baorui","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhe","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinchen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongquan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0952-9990","authenticated-orcid":true,"given":"Jinhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1902","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"ref2","first-page":"1830","volume-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","author":"Gordan","year":"2024"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000466"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.02.006"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30207-1"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32453-9"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000515552"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.175786"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03741-7"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412559"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-021-01487-w"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-21-0184"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-21-4140"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0159-1"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2442"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1172\/jci200317929"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00736-0"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.02.005"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1247005"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00322-0"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-105"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2015.05.007"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-11-0109"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3010445"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.01.261"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-4465"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.67.1891"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0695"},{"key":"ref30","first-page":"1039","volume-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","author":"Engelman","year":"2007"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-07-5229"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409773102"},{"key":"ref33","first-page":"3159","volume-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","author":"Olayioye","year":"2000"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m410436200"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-09-3321"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.4850"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108488"}],"container-title":["Clinical and Molecular Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2025-0972.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2025.0972","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2025-0972.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:58:14Z","timestamp":1776671894000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2025.0972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.3350\/cmh.2025.0972","relation":{},"ISSN":["2287-2728","2287-285X"],"issn-type":[{"value":"2287-2728","type":"print"},{"value":"2287-285X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"2025-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}